Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct 26;23(21):12910.
doi: 10.3390/ijms232112910.

Insights into the Genetics and Signaling Pathways in Maturity-Onset Diabetes of the Young

Affiliations
Review

Insights into the Genetics and Signaling Pathways in Maturity-Onset Diabetes of the Young

Madalena Sousa et al. Int J Mol Sci. .

Abstract

Diabetes Mellitus (DM) is a complex disease with a significant impact in today's world. Studies have emphasized the crucial role of genetics in DM, unraveling the distinction of monogenic diabetes from the most common types that have been recognized over the years, such as type 1 diabetes (T1DM) and type 2 diabetes (T2DM). A literature search was carried out to scrutinize the subtypes of maturity-onset diabetes of the young (MODY), as well as the connection between the recognized genetic and molecular mechanisms responsible for such phenotypes. Thus far, 14 subtypes of MODY have been identified. Here, the authors review the pathophysiological and molecular pathways in which monogenic diabetes genes are involved. Despite being estimated to affect approximately 2% of all T2DM patients in Europe, the exact prevalence of MODY is still unknown, enhancing the need for research focused on biomarkers. Due to its impact in personalized medicine, a follow-up of associated complications, and genetic implications for siblings and offspring of affected individuals, it is imperative to diagnose the monogenic forms of DM accurately. Currently, advances in the genetics field has allowed for the recognition of new DM subtypes, which until now were considered to be slight variations of the typical forms. New molecular insights can define therapeutic strategies, aiming for the prevention, correction, or at least delay of β-cell dysfunction. Thus, it is imperative to act in the close interaction between genetics and clinical manifestations to improve diagnosis and individualize treatment.

Keywords: diabetes mellitus; genetics; maturity-onset diabetes of the young; monogenic diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Roglic G., World Health Organization . Global Report on Diabetes. World Health Organization; Geneva, Switzerland: 2016. 86p
    1. Ellard S., Bellanné-Chantelot C., Hattersley A.T. Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia. 2008;51:546–553. doi: 10.1007/s00125-008-0942-y. - DOI - PMC - PubMed
    1. Anik A., Çatli G., Abaci A., Böber E. Maturity-onset diabetes of the young (MODY): An update. J. Pediatr. Endocrinol. Metab. 2015;28:251–263. doi: 10.1515/jpem-2014-0384. - DOI - PubMed
    1. Colclough K., Saint-Martin C., Timsit J., Ellard S., Bellanné-Chantelot C. Clinical utility gene card for: Maturity-onset diabetes of the young. Eur. J. Hum. Genet. 2014;22:1153. doi: 10.1038/ejhg.2014.14. - DOI - PMC - PubMed
    1. Lau H.H., Ng N.H.J., Loo L.S.W., Jasmen J.B., Teo A.K.K. The molecular functions of hepatocyte nuclear factors—In and beyond the liver. J. Hepatol. 2018;68:1033–1048. doi: 10.1016/j.jhep.2017.11.026. - DOI - PubMed

Supplementary concepts